![]() ![]() Therapeutic alternatives for these patients are a large gap in the field, and critically needed,” said Dr. “PD-1 blockade therapy has significantly improved clinical outcomes for many patients with cancer, although most patients still experience disease progression on anti−PD-1-therapy. The study treatment induced deep and durable systemic antitumor responses in patients with melanoma who previously progressed on anti-PD-1 treatments. Kirkwood, M.D., Director of the Melanoma and Skin Center at UPMC Hillman Cancer Center and Usher Professor of Medicine in the Division of Dermatology and Translational Science at the University of Pittsburgh School of Medicine, is presenting late-breaking final clinical data from the Checkmate-sponsored clinical trial of vidutolimod, either in combination with pembrolizumab or as monotherapy.įinal clinical data from the trial demonstrated that the combination of vidutolimod and pembrolizumab was well tolerated and resulted in an ORR of 23.5% according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. On Friday, November 12, 2021, during the Virtual Poster Hall Exhibit from 7:00am – 8:30pm ET, John M. Fuhrman added, “The RECIST response rates of 20% with vidutolimod monotherapy and 23.5% in combination with pembrolizumab are compelling, and the longer duration of response of 25.2 months in combination with PD-1 blockade provides a strong rationale for our ongoing development program.”įinal analysis: phase 1b study investigating intratumoral injection of Toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma ( Abstract #16269 poster #950 NCT02680184 ) “Our ongoing investigation of vidutolimod indicates promising clinical activity for patients with PD-1 blockade-refractory melanoma,” said Alan Fuhrman, interim President and Chief Executive Officer of Checkmate. ![]() 12, 2021 (GLOBE NEWSWIRE) - Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of final clinical data from the Phase 1b study, CMP-001-001 (NCT02680184), of vidutolimod, an advanced generation Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab or as a monotherapy at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting taking place on November 10-14, 2021. ![]() Vidutolimod also demonstrated monotherapy activity with an ORR of 20.0% per RECIST v1.1ĬAMBRIDGE, Mass., Nov. Vidutolimod in combination with pembrolizumab demonstrated promising clinical activity in patients with PD-1 blockade-refractory melanoma with an ORR of 23.5% per RECIST v1.1 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |